HomeCompareOMHE vs ABBV

OMHE vs ABBV: Dividend Comparison 2026

OMHE yields 6666666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OMHE wins by $8.25873857526507e+44M in total portfolio value
10 years
OMHE
OMHE
● Live price
6666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25873857526507e+44M
Annual income
$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00
Full OMHE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OMHE vs ABBV

📍 OMHE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOMHEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OMHE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OMHE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OMHE
Annual income on $10K today (after 15% tax)
$566,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OMHE beats the other by $701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OMHE + ABBV for your $10,000?

OMHE: 50%ABBV: 50%
100% ABBV50/50100% OMHE
Portfolio after 10yr
$4.129369287632535e+44M
Annual income
$412,924,744,481,180,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OMHE
No analyst data
Altman Z
0.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OMHE buys
0
ABBV buys
0
No recent congressional trades found for OMHE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOMHEABBV
Forward yield6666666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.25873857526507e+44M$102.3K
Annual income after 10y$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.258722632802889e+44M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OMHE vs ABBV ($10,000, DRIP)

YearOMHE PortfolioOMHE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$666,677,367$666,666,666.67$11,550$430.00+$666.67MOMHE
2$41,538,243,978,220$41,537,530,633,437.17$13,472$627.96+$41538243.96MOMHE
3$2,418,785,178,923,619,000$2,418,740,733,002,562,000.00$15,906$926.08+$2418785178923.60MOMHE
4$131,632,535,180,835,430,000,000$131,629,947,080,693,970,000,000.00$19,071$1,382.55+$131632535180835424.00MOMHE
5$6,694,929,569,421,761,000,000,000,000$6,694,788,722,609,116,000,000,000,000.00$23,302$2,095.81+$6.69492956942176e+21MOMHE
6$318,233,313,948,923,370,000,000,000,000,000$318,226,150,374,284,100,000,000,000,000,000.00$29,150$3,237.93+$3.1823331394892335e+26MOMHE
7$14,137,160,116,927,522,000,000,000,000,000,000,000$14,136,819,607,281,600,000,000,000,000,000,000,000.00$37,536$5,121.41+$1.4137160116927522e+31MOMHE
8$586,942,647,681,175,100,000,000,000,000,000,000,000,000$586,927,520,919,850,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$5.8694264768117504e+35MOMHE
9$22,774,359,015,829,920,000,000,000,000,000,000,000,000,000,000$22,773,730,987,196,898,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.277435901582992e+40MOMHE
10$825,873,857,526,507,000,000,000,000,000,000,000,000,000,000,000,000$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.25873857526507e+44MOMHE

OMHE vs ABBV: Complete Analysis 2026

OMHEStock

Omni Health, Inc., through its subsidiary, Malecon Pharmacy, Inc., operates a pharmacy in Hialeah, Florida. It provides health, wellness, and pharmacy services; and manufactures, sells, and distributes anti-aging cream. The company is headquartered in Hialeah, Florida. Omni Health, Inc. is a subsidiary of LX Retail Group, Inc.

Full OMHE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OMHE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OMHE vs SCHDOMHE vs JEPIOMHE vs OOMHE vs KOOMHE vs MAINOMHE vs JNJOMHE vs MRKOMHE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.